On September 12, 2022 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, reported that a poster describing the first-in-human Phase 1 trial design for LYL797, Lyell’s ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming for the treatment of solid tumors, is being presented today at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 in Paris, France (Press release, Lyell Immunopharma, SEP 12, 2022, View Source [SID1234619423]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This first-in-human Phase 1 trial is designed to provide important data on the potential of Lyell’s innovative reprogramming technologies to endow T cells with durable anti-tumor functionality," stated Dr. Tina Albertson, chief medical officer of Lyell. "These reprogramming technologies are designed to overcome primary barriers to sustained response to adoptive cell therapy for patients with solid tumor cancers, namely T-cell exhaustion and lack of durable stemness."
Details on the presentation are below:
Phase 1 Study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors
Category: Investigational Immunotherapy
Date, Time & Location: September 12, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4
Presentation number: 777TiP
About LYL797
LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. LYL797 incorporates Gen-R and Epi-R, Lyell’s novel reprogramming technologies designed to overcome primary barriers to successful adoptive cell therapy: T-cell exhaustion and lack of durable stemness. The Phase 1 trial will assess LYL797 in patients with relapsed/refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). More information can be found on ClinicalTrials.gov by searching NCT05274451.